Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas

@inproceedings{Laroche2017ActivityOT,
  title={Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas},
  author={Audrey Laroche and Vanessa Chaire and François Le Loarer and Marie-Paule Alg{\'e}o and Christophe Rey and Kevin Tran and Carlo Lucchesi and Antoine Italiano},
  booktitle={Journal of hematology & oncology},
  year={2017}
}
BACKGROUND Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success. The mechanism of action of trabectedin depends on the status of both the nucleotide excision repair (NER) and homologous recombination (HR) DNA repair pathways. Trabectedin results in DNA double-strand breaks. We hypothesized that PARP-1 inhibition is able to perpetuate trabectedin-induced DNA damage… CONTINUE READING
4 Extracted Citations
40 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 40 references

Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial

  • GD Demetri, M von Mehren, RL Jones, ML Hensley, SM Schuetze, A Staddon
  • J Clin Oncol. 2016;34:786–93
  • 2015

Synergistic effect of trabectedin and olaparib combination regimen in breast cancer cell lines

  • S Avilla-Arroyo, GS Nunez, LF Garcia-fernandez, CM. Galmaricini
  • J Breast Cancer
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…